Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

Illumina challenges EU order to keep Grail separate

Published Jan 10, 2023 07:58AM ET Updated Jan 10, 2023 10:41AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Illumina's global headquarters is pictured in San Diego, California, U.S., November, 28, 2022. REUTERS/Mike Blake/File Photo
 
ILMN
+0.48%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Foo Yun Chee

BRUSSELS (Reuters) -U.S. life sciences company Illumina (NASDAQ:ILMN) on Tuesday challenged an EU antitrust order to keep biotech firm Grail separate, ratcheting up its fight against EU regulators which blocked a merger deal last year.

Following its veto, the European Union competition enforcer renewed an interim measure last October requiring Illumina to keep Grail as a separate entity so the company can unwind a takeover it had completed without waiting for the deal to get EU approval.

"Today, we appealed the European Commission's interim measures order to hold separate Illumina and Grail," Illumina said in a statement.

"We disagree that the Commission has jurisdiction to review the merger, and with the premise of the interim measures itself and with a number of its provisions, the Commission has exceeded its authority," it said.

The EU executive said in emailed comment it would defend its case in court.

Illumina has three appeals pending in the Luxembourg courts, Europe's top courts, against the EU enforcer's ruling that it jumped the gun by closing the deal without securing approval, the EU's subsequent veto and the EU decision to examine the case.

Illumina challenges EU order to keep Grail separate
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Kevin Parker
Kevin Parker Jan 10, 2023 10:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
So this one feels like a big brown nose to me. We need Illumina, we need Grail. I would say continue to bring this incredible world changing technology to the market as fast as possible. Look how many people have died of Cancer in the past two decades. We need to bring these tests into the world along with a routing 'blood test' that's so primitive, it really detects very little in the way of cancer. Grail -> Yes! Illumina -> Yes! EU Regulators (on this issue) -> No!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email